Bernstein analyst Lance Wilkes downgraded Oak Street Health (OSH) to Market Perform from Outperform with a price target of $39, up from $35, following the takeover agreement with CVS Health (CVS). The analyst sees upside to the $39 per share offer price as being offset by risks to deal closure. Regulatory approval is taking longer as the Biden administration scrutinizes more deals, the analyst tells investors in a research note. The firm expects the deal will eventually be approved.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OSH:
- Oak Street Health downgraded to Market Perform from Outperform at Raymond James
- CVS Health price target raised to $143 from $130 at Jefferies
- Oak Street Health downgraded to Hold from Buy at Jefferies
- Oak Street Health downgraded to Market Perform from Outperform at William Blair
- Oak Street Health downgraded to Hold from Buy at Canaccord
